Statistics for A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian CancerA Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer
Total visits
| views | |
|---|---|
| A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian CancerA Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer | 82 |
Total visits per month
| views | |
|---|---|
| September 2024 | 0 |
| October 2024 | 0 |
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 0 |
File Visits
| views | |
|---|---|
| nihms-1546537.pdf | 138 |
| java.util.UUID:68676f85-9e74-4ffe-b29a-216b5415fbf5 | 47 |
| java.util.UUID:eabf6426-75c8-471f-a19b-0304dad35bd7 | 17 |
| java.util.UUID:3b43f047-d77f-4434-88c6-f52752f3e86a | 8 |
Top country views
| views | |
|---|---|
| United States | 61 |
| Canada | 3 |
| China | 1 |
| Germany | 1 |
| Malaysia | 1 |
| Sweden | 1 |
Top city views
| views | |
|---|---|
| Wilmington | 39 |
| Fairfield | 5 |
| Houston | 3 |
| Toronto | 3 |
| Ann Arbor | 2 |
| Cambridge | 2 |
| Baltimore | 1 |
| Duncan | 1 |
| Frankfurt Am Main | 1 |
| Mountain View | 1 |
| Seremban | 1 |
| Stockholm | 1 |